The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval of cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.
Ceftazidime-avibactam was highly active against a large collection of gram-negative bacteria isolated from patients with complicated urinary tract infections.
There is no increased risk for adverse genitourinary complications without the catheter
No net benefit seen for screening, treatment of asymptomatic bacteriuria for nonpregnant adults
Risk significantly increased for current use and recent use, but not past use within 61 to 365 days
Represcription rate at 28 days only 4.1% from 2011 to 2015; slight increase seen for men over time
Renal pelvis dilatation persisting in later pregnancy or after birth tied to increased risk for later admission
Children who have a second febrile UTI had a nearly 12 times higher risk of renal scarring than those who have a single febrile UTI, according to investigators.
Study finds no increased risks for severe or nonsevere urinary tract infections with SGLT-2 inhibitor use compared with other second-line antidiabetic drugs in type 2 diabetes patients.
The antibiotic Recarbrio is a combination of imipenem-cilastatin and relebactam.